vs
GoodRx Holdings, Inc.（GDRX）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是GoodRx Holdings, Inc.的1.1倍（$207.3M vs $194.8M），GoodRx Holdings, Inc.净利率更高（2.8% vs -62.0%，领先64.8%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -1.9%），GoodRx Holdings, Inc.自由现金流更多（$31.6M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -0.8%）
GoodRx是一家美国医疗健康企业，运营着远程医疗平台以及可免费使用的网站与移动应用，服务覆盖美国超75000家药店，可为用户追踪处方药价格、提供药品优惠折扣券，还支持用户在线问诊，获取部分品类药物的处方。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
GDRX vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $194.8M | $207.3M |
| 净利润 | $5.4M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 11.6% | -54.7% |
| 净利率 | 2.8% | -62.0% |
| 营收同比 | -1.9% | 25.9% |
| 净利润同比 | -19.5% | 3.5% |
| 每股收益（稀释后） | $0.02 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $194.8M | $207.3M | ||
| Q3 25 | $196.0M | $159.9M | ||
| Q2 25 | $203.1M | $166.5M | ||
| Q1 25 | $203.0M | $139.3M | ||
| Q4 24 | $198.6M | $164.6M | ||
| Q3 24 | $195.3M | $139.5M | ||
| Q2 24 | $200.6M | $147.0M | ||
| Q1 24 | $197.9M | $108.8M |
| Q4 25 | $5.4M | $-128.6M | ||
| Q3 25 | $1.1M | $-180.4M | ||
| Q2 25 | $12.8M | $-115.0M | ||
| Q1 25 | $11.1M | $-151.1M | ||
| Q4 24 | $6.7M | $-133.2M | ||
| Q3 24 | $4.0M | $-133.5M | ||
| Q2 24 | $6.7M | $-131.6M | ||
| Q1 24 | $-1.0M | $-170.7M |
| Q4 25 | 11.6% | -54.7% | ||
| Q3 25 | 7.5% | -106.9% | ||
| Q2 25 | 13.2% | -64.8% | ||
| Q1 25 | 11.5% | -102.6% | ||
| Q4 24 | 9.2% | -74.3% | ||
| Q3 24 | 10.5% | -94.6% | ||
| Q2 24 | 9.9% | -79.1% | ||
| Q1 24 | 3.7% | -151.9% |
| Q4 25 | 2.8% | -62.0% | ||
| Q3 25 | 0.6% | -112.8% | ||
| Q2 25 | 6.3% | -69.0% | ||
| Q1 25 | 5.4% | -108.5% | ||
| Q4 24 | 3.4% | -80.9% | ||
| Q3 24 | 2.0% | -95.7% | ||
| Q2 24 | 3.3% | -89.5% | ||
| Q1 24 | -0.5% | -156.8% |
| Q4 25 | $0.02 | $-1.28 | ||
| Q3 25 | $0.00 | $-1.81 | ||
| Q2 25 | $0.04 | $-1.17 | ||
| Q1 25 | $0.03 | $-1.57 | ||
| Q4 24 | $0.01 | $-1.34 | ||
| Q3 24 | $0.01 | $-1.40 | ||
| Q2 24 | $0.02 | $-1.52 | ||
| Q1 24 | $0.00 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $261.8M | $421.0M |
| 总债务越低越好 | $495.0M | — |
| 股东权益账面价值 | $616.3M | $-80.0M |
| 总资产 | $1.4B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.80× | — |
8季度趋势，按日历期对齐
| Q4 25 | $261.8M | $421.0M | ||
| Q3 25 | $273.5M | $202.5M | ||
| Q2 25 | $281.3M | $176.3M | ||
| Q1 25 | $301.0M | $127.1M | ||
| Q4 24 | $448.3M | $174.0M | ||
| Q3 24 | $423.8M | $150.6M | ||
| Q2 24 | $524.9M | $480.7M | ||
| Q1 24 | $533.3M | $112.3M |
| Q4 25 | $495.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $500.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $616.3M | $-80.0M | ||
| Q3 25 | $600.7M | $9.2M | ||
| Q2 25 | $643.0M | $151.3M | ||
| Q1 25 | $654.3M | $144.2M | ||
| Q4 24 | $724.7M | $255.0M | ||
| Q3 24 | $696.4M | $346.8M | ||
| Q2 24 | $669.4M | $432.4M | ||
| Q1 24 | $631.1M | $140.3M |
| Q4 25 | $1.4B | $1.5B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.3B | $1.3B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.4B | $1.5B | ||
| Q3 24 | $1.4B | $1.5B | ||
| Q2 24 | $1.5B | $1.6B | ||
| Q1 24 | $1.5B | $1.3B |
| Q4 25 | 0.80× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.69× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $31.6M | $-100.8M |
| 自由现金流率自由现金流/营收 | 16.2% | -48.6% |
| 资本支出强度资本支出/营收 | 0.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 6.06× | — |
| 过去12个月自由现金流最近4个季度 | $164.4M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $32.9M | $-99.8M | ||
| Q3 25 | $76.0M | $-91.4M | ||
| Q2 25 | $49.6M | $-108.3M | ||
| Q1 25 | $9.4M | $-166.5M | ||
| Q4 24 | $44.7M | $-79.3M | ||
| Q3 24 | $86.9M | $-67.0M | ||
| Q2 24 | $9.7M | $-77.0M | ||
| Q1 24 | $42.6M | $-190.7M |
| Q4 25 | $31.6M | $-100.8M | ||
| Q3 25 | $74.3M | $-92.7M | ||
| Q2 25 | $49.2M | $-110.7M | ||
| Q1 25 | $9.3M | $-167.8M | ||
| Q4 24 | $44.6M | $-79.5M | ||
| Q3 24 | $86.5M | $-68.6M | ||
| Q2 24 | $9.4M | $-79.0M | ||
| Q1 24 | $42.2M | $-193.9M |
| Q4 25 | 16.2% | -48.6% | ||
| Q3 25 | 37.9% | -58.0% | ||
| Q2 25 | 24.2% | -66.5% | ||
| Q1 25 | 4.6% | -120.5% | ||
| Q4 24 | 22.4% | -48.3% | ||
| Q3 24 | 44.3% | -49.2% | ||
| Q2 24 | 4.7% | -53.7% | ||
| Q1 24 | 21.3% | -178.2% |
| Q4 25 | 0.6% | 0.5% | ||
| Q3 25 | 0.9% | 0.8% | ||
| Q2 25 | 0.2% | 1.5% | ||
| Q1 25 | 0.1% | 1.0% | ||
| Q4 24 | 0.1% | 0.1% | ||
| Q3 24 | 0.2% | 1.2% | ||
| Q2 24 | 0.1% | 1.4% | ||
| Q1 24 | 0.2% | 3.0% |
| Q4 25 | 6.06× | — | ||
| Q3 25 | 67.94× | — | ||
| Q2 25 | 3.86× | — | ||
| Q1 25 | 0.85× | — | ||
| Q4 24 | 6.64× | — | ||
| Q3 24 | 21.91× | — | ||
| Q2 24 | 1.45× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GDRX
| Prescription Transactions Revenue | $124.7M | 64% |
| Other | $44.4M | 23% |
| Subscription Revenue | $21.6M | 11% |
| Other Revenue | $4.1M | 2% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
